MONOCLONAL ANTIBODIES AGAINST RGM PROTEIN FOR USE IN TREATMENT OF RETINAL NERVE FIBER LAYER DEGENERATION

To provide antibodies that can bind to RGM A of RNFL degeneration observed in a multiplicity of disease conditions.SOLUTION: The invention provides a RGM A binding protein having an ability to bind to RGM A to inhibit the binding of RGM protein to RGM A receptor and other RGM A binding proteins and therefore to neutralize the function of RGM A, particularly a monoclonal antibody, in particular, a CDR grafted and humanized version thereof for use in treatment of retinal nerve fiber layer degeneration. The invention also provides a method for therapeutically or prophylactically treating a mammal against RNFL degeneration.SELECTED DRAWING: None 【課題】多数の病状で観察されるＲＮＦＬ変性のＲＧＭ Ａに結合できる抗体の提供。【解決手段】網膜神経線維層（ＲＮＦＬ）変性の治療に使用するためのＲＧＭ Ａに結合し、ＲＧＭタンパク質のＲＧＭ Ａ受容体及び他のＲＧＭ Ａ結合タンパク質に対する結合を妨げ、よってＲＧＭ Ａの機能を中和する能力を有するＲＧＭ Ａ結合タンパク質、特にモノクローナル抗体、とりわけそのＣＤＲグラフト化ヒト化バージョン、並びにＲＮＦＬ変性を防ぐために哺乳動物を治療上または予防上治療する方法を提供する。【選択図】なし